Insmed reported $1.93B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Dynavax Technologies USD 814.33M 28.62M Sep/2025
Gilead Sciences USD 18.84B 4.12B Sep/2025
Insmed USD 1.93B 149.77M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 10.57B 141.7M Sep/2025